Prediction Augmented Screening Initiative

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-80
SponsorVA Office of Research and Development

About this trial

Lung cancer is responsible for more deaths in the United States than breast, prostate and colon cancer combined and is the number one cancer killer of Veterans. This is because lung cancer is usually diagnosed when the disease has spread, and cure is less likely. Lung cancer screening (LCS) finds cancer at an earlier stage when it is curable, yet only 20% of eligible Veterans have been screened. Uptake is even lower among Black Veterans despite higher lung cancer risk. Using prediction models to identify high-benefit people for whom LCS should be encouraged improves efficiency and reduces disparities. Moreover, it is more patient-centered as shared decision-making conversations can be tailored with personalized information. The US Preventive Services Task Force has called for research to demonstrate that prediction-augmented LCS can be feasibly implemented at the point-of-care. The investigators propose for VA to lead this effort with a large-scale pragmatic clinical trial to show that prediction-augmented LCS is both feasible and improves LCS uptake.

Eligibility criteria

Qualifiers

meeting USPSTF eligibility criteria for LCS, as currently encoded in the background logic of LCS clinical reminders maintained by the VA National Center for Lung Cancer Screening (i.e., age 50-80 years; smoked 20 pack-years; current smoking or quit <15 years ago) OR

predicted benefit calculated using LYFS-CTVA model exceeds a stringent high-benefit threshold of life-year gains with annual LCS, as recommended in the 2021 CHEST LCS guidelines

Disqualifiers

Veterans who have previously undergone lung cancer screening, are diagnosed with lung cancer, or who do not meet eligibility criteria outlined above

Trial design

Treatments tested in this trial

  • PCP-Facing Tools
  • LCS team population management tools

Treatment groups

23,520 Participants
are divided into 4 treatment groups

Locations

4
VA Bedford HealthCare System, Bedford, MA01730-1114, BedfordMassachusetts, United States
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA02130-4817, BostonMassachusetts, United States
VA Ann Arbor Healthcare System, Ann Arbor, MI48105-2303, Ann ArborMichigan, United States
Ralph H. Johnson VA Medical Center, Charleston, SC29401-5703, CharlestonSouth Carolina, United States

Sponsors and collaborators

VA Office of Research and Development

Lead sponsor